Skip to main content
      RT @RichardPAConway: Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis

      Richard Conway RichardPAConway

      4 years ago
      Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN
      Prolonging the Controversy of Hydroxychloroquine

      Dr. Kathryn Dao (@KDAO2011 ) shares several abstracts from #ACR21 tha

      Dr. John Cush RheumNow

      4 years ago
      Prolonging the Controversy of Hydroxychloroquine Dr. Kathryn Dao (@KDAO2011 ) shares several abstracts from #ACR21 that addressed the topic of HCQ and cardiovascular safety. https://t.co/J6sVzYJkUZ https://t.co/dBZmtwQ927
      RT @DrMiniDey: My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in

      Mrinalini Dey DrMiniDey

      4 years ago
      My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK #axspa #spondyloarthritis #arthritis #qualityoflife Watch it here👇🏼 https://t.co/MEQ4wkFxrx
      RT @Yuz6Yusof: #ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, cl

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago

      #ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ

      RT @DrMiniDey: A key reason I'm looking forward to in-person conferences again, is so I don't have to perform the mental

      Mrinalini Dey DrMiniDey

      4 years ago
      A key reason I'm looking forward to in-person conferences again, is so I don't have to perform the mental gymnastics and stress of ensuring I make all the sessions and meetings on time! 😂 ⏰UK colleagues- time difference for #ACR21 will be +5️hours from tomorrow! @RheumNow https://t.co/wl7ij3vyOU
      RT @synovialjoints: There is a strong association with pre-ICI autoantibody positivity and any-type irAE development as

      Dr. Antoni Chan synovialjoints

      4 years ago
      There is a strong association with pre-ICI autoantibody positivity and any-type irAE development as well as high specificity of RF and CCP for ICI-arthritis. Prospective evaluation of RF/CCP pre-treatment may be useful @RheumNow #ACR21 Abst#0440 https://t.co/P7L7pL1iuV
      RT @Janetbirdope: Excellent debate in #Lupus nephritis 6S214 with Wofsy, Isenberg & Costenbader. Q’s. What to do a

      Janet Pope Janetbirdope

      4 years ago
      Excellent debate in #Lupus nephritis 6S214 with Wofsy, Isenberg & Costenbader. Q’s. What to do about Class V renal, many class III, IV LNdon’t go into sustained remission, cases of new onset LN in pts with #Belimumab ?more/less than expected, which drug to use @RheumNow #ACR21 https://t.co/tWbw79dE7d
      RT @swethaann23: Torgutalp et al.
      ⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-ax

      swethaann23 swethaann23

      4 years ago
      Torgutalp et al. ⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort ⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression. Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by Rhe

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
      RT @doctorRBC: IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers?

      ⬆️IL-22 in AxSpA vs. contro

      Robert B Chao, MD doctorRBC

      4 years ago
      IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers? ⬆️IL-22 in AxSpA vs. controls ⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP Abs#385 #ACR21 @RheumNow https://t.co/hNtStAluJH
      RT @Yuz6Yusof: #ACR21 #Abstr0189 Another case for early intervention. Median time-to-Rilonacept (IL1-i) monotherapy for

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 #Abstr0189 Another case for early intervention. Median time-to-Rilonacept (IL1-i) monotherapy for recurrent pericarditis was 7.9 weeks! During this time, >94% pts discontinued steroid and/or colchicine either sequentially or concurrently @RheumNow https://t.co/ofi3Jtm6j6 https://t.co/b6PnFw4gUN
      RT @DrMiniDey: Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #Alz

      Mrinalini Dey DrMiniDey

      4 years ago
      Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #AlzheimersDisease & related #dementia in RA pts. 👉~1300 patients 👉Among CVD conditions, #stroke & #CHF assoc w/ the risk of #dementia #ACR21 Abs#0284 @RheumNow https://t.co/N3x2ZtBFGe https://t.co/kFyf3A0gha
      ×